AGrigorjeva/iStock/GettyImages
Gene‑engineering traces back to 1913 when Alfred Sturtevant, an American geneticist, produced the first chromosomal genetic map for his doctoral thesis. He demonstrated genetic linkage during meiosis, showing how parental chromosomes halve to form sperm and egg cells.
Following the 1953 discovery of DNA’s double helix by Francis Crick and James Watson, Frederick Sanger developed a method to sequence DNA, assigning the four nucleotide bases—adenine (A), thymine (T), guanine (G), and cytosine (C). By the 1980s, sequencing was fully automated.
In 1988, the U.S. Congress funded the National Institutes of Health and the Department of Energy to coordinate research on the human genome. The Human Genome Project, initially expected to span decades, mapped 90% of the genome by 2000 and completed its full sequencing in 2003—just 50 years after the double‑helix breakthrough.
DNA’s base‑pairing rules (A with T, G with C) were confirmed, revealing approximately 3 billion base pairs arranged in 23 chromosome pairs in human nuclei.
Fast forward to August 2017, when international teams from Oregon, California, Korea, and China applied CRISPR‑9— a gene‑editing technology—to correct a hereditary heart‑defect gene (MYBPC3) in human embryos. The defect, hypertrophic cardiomyopathy, leads to sudden death in young athletes and affects about 1 in 500 individuals.
Two approaches were tested. The first involved fertilizing eggs with sperm carrying the defective MYBPC3 gene, then removing the mutation and inserting healthy DNA. While this method successfully repaired 36 of 54 embryos, 13 embryos lacked the mutation yet contained some affected cells, showing inconsistent results.
The second approach introduced CRISPR scissors into the egg before fertilization, targeting mitochondrial DNA. This yielded a 72% success rate—42 of 58 embryos were mutation‑free, though 16 contained off‑target DNA. All embryos were discarded after three days, preventing any developmental outcome.
Germline editing remains ineffective when both parents carry the same defective gene, underscoring the need for further trials. Current U.S. federal law restricts government funding for germline research, limiting progress. Funding for the 2017 study came from South Korea’s Institute for Basic Science, Oregon Health & Science University, and private foundations.
While the idea of tailoring infant traits—like musical talent or athletic prowess—captures public imagination, it remains scientifically unattainable. Human height, for instance, involves roughly 93,000 gene variants. As Hank Greely, director of the Center for Law and the Biosciences at Stanford, noted in the New York Times, "We can’t predict that an embryo will score a specific SAT score or possess a particular talent; these traits arise from complex gene interactions."
Germline engineering shows promise for preventing inherited diseases, offering hope to families with known congenital conditions. However, for most couples, the high cost and ethical debates—along with the sentiment that natural conception is preferable—make gene editing unlikely to become routine. Bioethicist Dr. R. Alta Charo of the University of Wisconsin‑Madison emphasizes that "sex is more fun," highlighting societal reluctance.
As technology advances, the debate over germline editing, gene therapy, and the possibility of designer babies will persist, demanding careful ethical, legal, and scientific scrutiny.
